Breast Cancer Liquid Biopsy Market Size, Share and Growth Outlook, 2026

Breast Cancer Liquid Biopsy Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Breast Cancer Liquid Biopsy Market size is forecast to increase from $1.41 Billion in 2026 to $2.77 Billion in 2034 at a CAGR of 8.8% between 2026 and 2034.

The Breast Cancer Liquid Biopsy market report provides detailed analysis and outlook of Breast Cancer Liquid Biopsy segments including By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cells, Extracellular Vesicles, Circulating RNA ), By Product & Service (Assay Kits & Reagents, Instruments & Platforms, Testing & Laboratory Services), By Clinical Application (Early Detection & Screening, Treatment Selection & Companion Diagnostics, Minimal Residual Disease, Treatment Response & Resistance Tracking), By End-User (Reference & Independent Diagnostic Laboratories, Hospitals & Cancer Institutes, Biopharmaceutical & Biotechnology Companies, Academic & Research Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Breast Cancer Liquid Biopsy Industry Overview

Next-Generation Multiomic Liquid Biopsy Platforms Advancing Precision Oncology

The breast cancer liquid biopsy industry is rapidly advancing through the integration of genomic, epigenomic, and artificial intelligence technologies that enhance cancer detection and treatment selection. Guardant Health received U.S. FDA approval for its next-generation Guardant360® Liquid CDx, a comprehensive blood-based genomic testing platform that combines genomic profiling with DNA methylation-based epigenomic analysis. Powered by the company’s proprietary Smart Platform and advanced artificial intelligence capabilities, the assay features a genomic footprint that is 100 times larger than its predecessor, enabling significantly improved sensitivity for circulating tumor DNA (ctDNA) detection. Importantly, the platform retains all seven previously approved companion diagnostic indications and remains the only FDA-approved liquid biopsy companion diagnostic for targeted therapies in advanced breast cancer patients harboring ESR1 mutations. The integration of genomic and epigenomic biomarkers into a single liquid biopsy workflow highlights the industry's movement toward more comprehensive molecular characterization of breast cancer through minimally invasive blood testing.

Dual-Modality Diagnostic Ecosystems Expanding Patient Access to Targeted Therapies

The breast cancer liquid biopsy market is increasingly adopting complementary testing strategies that combine tissue-based and blood-based diagnostics to ensure broader patient eligibility for precision therapies. Foundation Medicine received FDA approval for FoundationOne®CDx tissue testing as a companion diagnostic for Genentech’s Itovebi™ (inavolisib), indicated for endocrine-resistant, PIK3CA-mutated, HR-positive/HER2-negative advanced or metastatic breast cancer. This approval was specifically designed to complement FoundationOne®Liquid CDx, which had previously received approval for the same therapeutic indication. The dual-modality diagnostic ecosystem addresses a critical clinical challenge involving tumors that release insufficient quantities of cell-free DNA (cfDNA) into the bloodstream for reliable liquid biopsy analysis. By providing both blood-based and tissue-based testing pathways, healthcare providers can more effectively identify eligible patients for targeted treatment while minimizing the risk of missed molecular diagnoses. This integrated diagnostic approach is becoming increasingly important within precision oncology frameworks.

Machine Learning and Functional Tumor Biology Driving Next-Generation Liquid Biopsy Research

Emerging liquid biopsy technologies are extending beyond mutation detection to provide deeper insights into functional tumor biology and therapeutic response mechanisms. Precede Biosciences launched Precede Bio Insight™, a genome-wide liquid biopsy platform developed for research applications. The technology utilizes machine learning algorithms to analyze cell-free DNA fragmentation patterns obtained from only 1 mL of blood plasma. Unlike conventional liquid biopsy systems that primarily focus on somatic mutation identification, the platform infers gene expression activity, pathway signaling dynamics, and broader functional characteristics of tumor biology. This capability enables researchers to monitor functional cellular states, identify emerging resistance mechanisms, and evaluate biological responses to advanced treatments such as antibody-drug conjugates (ADCs). The growing application of machine learning-driven cfDNA analysis is expanding the scientific value of liquid biopsy technologies and supporting more comprehensive molecular understanding of advanced breast cancer progression and treatment response.

Breast Cancer Liquid Biopsy Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Breast Cancer Liquid Biopsy market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- F. Hoffmann-La Roche Ltd, Illumina, Inc., Guardant Health, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Exact Sciences Corporation, Natera, Inc., Bio-Rad Laboratories, Inc., Myriad Genetics, Inc., Sysmex Corporation. The Breast Cancer Liquid Biopsy market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Breast Cancer Liquid Biopsy industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Breast Cancer Liquid Biopsy Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Breast Cancer Liquid Biopsy companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Breast Cancer Liquid Biopsy markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Breast Cancer Liquid Biopsy Market Competitive Benchmarking and Company Analysis

Leading companies in Breast Cancer Liquid Biopsy industry include- F. Hoffmann-La Roche Ltd, Illumina, Inc., Guardant Health, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Exact Sciences Corporation, Natera, Inc., Bio-Rad Laboratories, Inc., Myriad Genetics, Inc., Sysmex Corporation. The Breast Cancer Liquid Biopsy market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Breast Cancer Liquid Biopsy Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Breast Cancer Liquid Biopsy market remains one of the strongest-performing segments in the country.
The US Breast Cancer Liquid Biopsy Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Breast Cancer Liquid Biopsy market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Breast Cancer Liquid Biopsy industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Breast Cancer Liquid Biopsy markets

Canada's strong Breast Cancer Liquid Biopsy sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Breast Cancer Liquid Biopsy market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Breast Cancer Liquid Biopsy Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Breast Cancer Liquid Biopsy market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Breast Cancer Liquid Biopsy population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Breast Cancer Liquid Biopsy industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Breast Cancer Liquid Biopsy market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Breast Cancer Liquid Biopsy sales through 2034

France Breast Cancer Liquid Biopsy companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Breast Cancer Liquid Biopsy Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Breast Cancer Liquid Biopsy distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Breast Cancer Liquid Biopsy Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Breast Cancer Liquid Biopsy market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Breast Cancer Liquid Biopsy industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Breast Cancer Liquid Biopsy industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Breast Cancer Liquid Biopsy Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Breast Cancer Liquid Biopsy market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Breast Cancer Liquid Biopsy market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Breast Cancer Liquid Biopsy Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Breast Cancer Liquid Biopsy Market Segmentation

By Circulating Biomarker
Circulating Tumor DNA
Circulating Tumor Cells
Extracellular Vesicles
Circulating RNA
By Product & Service
Assay Kits & Reagents
Instruments & Platforms
Testing & Laboratory Services
By Clinical Application
Early Detection & Screening
Treatment Selection & Companion Diagnostics
Minimal Residual Disease
Treatment Response & Resistance Tracking
By End-User
Reference & Independent Diagnostic Laboratories
Hospitals & Cancer Institutes
Biopharmaceutical & Biotechnology Companies
Academic & Research Centers

Top Companies in Breast Cancer Liquid Biopsy Industry

F. Hoffmann-La Roche Ltd
Illumina, Inc.
Guardant Health, Inc.
QIAGEN N.V.
Thermo Fisher Scientific Inc.
Exact Sciences Corporation
Natera, Inc.
Bio-Rad Laboratories, Inc.
Myriad Genetics, Inc.
Sysmex Corporation

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025